ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "William Leonard Pickard x Jonathan Sporn: Ibogaine & Innovation"
Episode Synopsis
🎙️ JLS Podcast: Leaders in Biotech Interview with Jonathan Sporn, CEO of Gilgamesh Pharmaceuticals
🚀 Company Background Founded 4 years ago with a $5,000 investment, now raised $80M in Series A funding. NIH awarded $13M in non-dilutive grants. AbbVie investment: $60M upfront, $2B in milestone payments—largest psychedelic deal in history.
🧪 Origins of Gilgamesh Pharmaceuticals Jonathan Sporn (ex-Pfizer, Harvard MD) partnered with Columbia University chemists to design novel psychedelic-inspired molecules. Initial research began in a Columbia lab, licensing certain assets while ensuring company research remained independent.
🔬 Gilgamesh’s Four Research Tracks
1️⃣ 🌀 5-HT2A Psychedelic Therapy Goal: Shorten the duration of psychedelic experiences for clinical use. Lead compound: 5-HT2A agonist with 45-minute half-life (vs. Psilocybin’s 2.5 hours). Current Status: Undergoing Phase 2 trials.
2️⃣ 🧠 Neuroplasticity Program (AbbVie Partnership) Focus: Non-hallucinogenic compounds that promote rapid antidepressant effects. Potential applications: Anxiety, depression, PTSD. Researching long-term cognitive and emotional restructuring without a "trip."
3️⃣ 💊 Ketamine/NMDA Antagonist Derivatives Goal: Oral alternative to ketamine with reduced dissociative and addictive effects. Key improvement: No opioid receptor binding (vs. Esketamine’s weak Mu opioid affinity).
4️⃣ 🌱 Ibogaine Analogs (NIH-funded) Target: Addiction treatment (opioids, meth, alcohol) with reduced cardiotoxicity risks. Developing novel compounds with Ibogaine’s efficacy but improved safety.
🔮 Broader Implications & Future of Psychedelic Medicine Neuroplasticity drugs may reshape mental health treatment beyond just symptom relief. Potential applications in cognitive enhancement, PTSD, and personality restructuring. Regulatory hurdles exist, particularly balancing psychotherapy with pharmaceutical models.
📡 Future of Drug Development & AI’s Role Gilgamesh employs AI-assisted drug discovery for compound screening. AI-generated molecules could accelerate development timelines dramatically. Maintains traditional chemistry-driven approach but open to AI advancements.
🏆 Final Takeaways Gilgamesh is positioned as the leading psychedelic biotech firm, with major funding and diverse R&D. Expect major updates in Q1 of the year. Public and private funding (NIH, AbbVie) signals mainstream biotech confidence in psychedelics.
✨ Support this work and unlock exclusive interviews with Bryan Hubbard, biotech CEOs, ethicists, and pioneers in AI drug design on Patreon:
https://www.patreon.com/c/thelastalchemist
🔗 Stay tuned for groundbreaking developments in psychedelic medicine!
🚀 Company Background Founded 4 years ago with a $5,000 investment, now raised $80M in Series A funding. NIH awarded $13M in non-dilutive grants. AbbVie investment: $60M upfront, $2B in milestone payments—largest psychedelic deal in history.
🧪 Origins of Gilgamesh Pharmaceuticals Jonathan Sporn (ex-Pfizer, Harvard MD) partnered with Columbia University chemists to design novel psychedelic-inspired molecules. Initial research began in a Columbia lab, licensing certain assets while ensuring company research remained independent.
🔬 Gilgamesh’s Four Research Tracks
1️⃣ 🌀 5-HT2A Psychedelic Therapy Goal: Shorten the duration of psychedelic experiences for clinical use. Lead compound: 5-HT2A agonist with 45-minute half-life (vs. Psilocybin’s 2.5 hours). Current Status: Undergoing Phase 2 trials.
2️⃣ 🧠 Neuroplasticity Program (AbbVie Partnership) Focus: Non-hallucinogenic compounds that promote rapid antidepressant effects. Potential applications: Anxiety, depression, PTSD. Researching long-term cognitive and emotional restructuring without a "trip."
3️⃣ 💊 Ketamine/NMDA Antagonist Derivatives Goal: Oral alternative to ketamine with reduced dissociative and addictive effects. Key improvement: No opioid receptor binding (vs. Esketamine’s weak Mu opioid affinity).
4️⃣ 🌱 Ibogaine Analogs (NIH-funded) Target: Addiction treatment (opioids, meth, alcohol) with reduced cardiotoxicity risks. Developing novel compounds with Ibogaine’s efficacy but improved safety.
🔮 Broader Implications & Future of Psychedelic Medicine Neuroplasticity drugs may reshape mental health treatment beyond just symptom relief. Potential applications in cognitive enhancement, PTSD, and personality restructuring. Regulatory hurdles exist, particularly balancing psychotherapy with pharmaceutical models.
📡 Future of Drug Development & AI’s Role Gilgamesh employs AI-assisted drug discovery for compound screening. AI-generated molecules could accelerate development timelines dramatically. Maintains traditional chemistry-driven approach but open to AI advancements.
🏆 Final Takeaways Gilgamesh is positioned as the leading psychedelic biotech firm, with major funding and diverse R&D. Expect major updates in Q1 of the year. Public and private funding (NIH, AbbVie) signals mainstream biotech confidence in psychedelics.
✨ Support this work and unlock exclusive interviews with Bryan Hubbard, biotech CEOs, ethicists, and pioneers in AI drug design on Patreon:
https://www.patreon.com/c/thelastalchemist
🔗 Stay tuned for groundbreaking developments in psychedelic medicine!
In God we trust